Tag - Zylö Therapeutics

04 Jun

Zylö Therapeutics Closes $5.225 Million Series B Financing

Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium of seasoned investors, spearheaded by James Cordes, who recently joined the Zylö board of directors. Other key participants were: (i) VentureSouth (which led the Series A round) which invested more than $1.3 million in the Series B round; (ii) the New York Angels, an angel group that has […]

Portfolio News Read more...
23 Dec

Startup: Zylö Therapeutics — Small company, big idea

Scott Pancoast believes he can put Greenville on the map with his company’s product, and he’s ready to take it to the world. Zylö Therapeutics is a technology startup that uses a silica powder, called Z-pods — very similar in consistency to talcum powder — to be the vehicle of transport for everything from pain relievers to pesticides. The Z-pods have far-reaching medical applications, as they’ve shown promise in promoting hair growth, treating acne, relieving pain, helping with erectile […]

Portfolio News Read more...
19 Nov

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Read more >>

Portfolio News Read more...
08 Oct

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Read more >>

Portfolio News Read more...
04 Sep

NEXT Venture Pitch finalists

…Billed as the “premiere venture pitch of the Carolinas,” NEXT gives entrepreneurs a chance to pitch ideas to investors, venture capitalists and community leaders. One of the six finalists is: Zylö Therapeutics — Next-gen, topical drug delivery systems. Read more >>

Portfolio News Read more...
12 Aug

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

Silo Pharma, Inc., a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Read more >>

Portfolio News Read more...